2897 related articles for article (PubMed ID: 7167445)
1. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
Schroit AJ; Fidler IJ
Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
[No Abstract] [Full Text] [Related]
2. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
3. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.
Saiki I; Milas L; Hunter N; Fidler IJ
Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858
[TBL] [Abstract][Full Text] [Related]
4. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
5. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
6. Role of alveolar macrophages in pulmonary neoplasias.
Sone S
Biochim Biophys Acta; 1986; 823(3):227-45. PubMed ID: 2423125
[No Abstract] [Full Text] [Related]
7. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.
Koff WC; Showalter SD; Hampar B; Fidler IJ
Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772
[TBL] [Abstract][Full Text] [Related]
8. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
9. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
11. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.
Fidler IJ
Cancer Immunol Immunother; 1986; 21(3):169-73. PubMed ID: 3698058
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.
Dinney CP; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1992 Mar; 52(5):1155-61. PubMed ID: 1531322
[TBL] [Abstract][Full Text] [Related]
13. Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease.
Poste G; Kirsh R
Prog Clin Biol Res; 1982; 102 pt A():309-19. PubMed ID: 7167443
[No Abstract] [Full Text] [Related]
14. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
15. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis.
Killion JJ; Fidler IJ
Immunomethods; 1994 Jun; 4(3):273-9. PubMed ID: 7820457
[TBL] [Abstract][Full Text] [Related]
16. [The effect of muramyl dipeptide analog, GMPD, incorporated into liposomes of various composition on the functional activity of macrophages].
Stefanov AV; Bondar' OP; Umanskiĭ VIu; Lishko VK; Baletskiĭ KP
Ukr Biokhim Zh (1978); 1989; 61(6):63-9. PubMed ID: 2561033
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
18. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
[TBL] [Abstract][Full Text] [Related]
19. [Antimetastatic effect of a liposome-enclosed analog of muramyl dipeptide].
Umanskiĭ VIu; Stefanov AV; Bondar' OP; Balitskiĭ KP; Pinchuk VG
Vopr Onkol; 1988; 34(4):433-8. PubMed ID: 2837005
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease.
Fidler IJ; Poste G
Springer Semin Immunopathol; 1982; 5(2):161-74. PubMed ID: 6755782
[No Abstract] [Full Text] [Related]
[Next] [New Search]
